On January 1, 2026, nonprofit Civica Rx launched insulin glargine pens at $55 a box; California debuted its CalRx-branded insulin the same day at the same price. Both undercut branded products by up to 90%: no insurance forms, no rebates, no hidden markups, just one transparent price for anyone, in a market three pharmaceutical giants control with a 90% share.
Behind those launches lie eight years of tragedy. Patients died after rationing insulin they couldn't afford; prices rose 1,200% over two decades; a byzantine rebate system enriched middlemen while forcing diabetics to choose between medication and rent.
The Civica and CalRx launches, alongside manufacturer price cuts, Medicare caps, state copay laws, and an ongoing FTC lawsuit against pharmacy benefit managers, are the first coordinated counteroffensive combining nonprofit competition, state intervention, and federal enforcement. Can these efforts permanently dismantle the pricing machinery? Or will pharmaceutical companies and pharmacy benefit managers find new ways to extract profits from the 8.4 million Americans who need insulin to survive?
People who rely on insulin for survival, making price increases literally life-or-death
1,200%
Price increase for Humalog (1999-2019)
One vial went from $21 to $332 in twenty years
$55
Civica & CalRx insulin glargine price (5 pens)
Compared to $150-$500 for equivalent branded products
1 in 4
Diabetic patients who ration insulin
Due to cost, risking blindness, kidney failure, coma, or death
$35
Maximum copay in Medicare & California
Federal cap for Medicare (2023), California cap for private insurance (2026)
2 states
Producing their own insulin
California first to launch; Minnesota exploring similar program
90%
Market share of three insulin makers
Eli Lilly, Novo Nordisk, and Sanofi dominate U.S. market
Voices
Curated perspectives — historical figures and your fellow readers.
Dorothy Parker
(1893-1967) ·Jazz Age · wit
Fictional AI pastiche — not real quote.
"How touching that it took only eight years of corpses and a 1,200% markup for capitalism to discover that perhaps diabetics shouldn't have to auction their kidneys to afford the insulin that keeps them alive. One does wonder what delayed the epiphany—was it the death toll, or merely that there weren't enough middlemen getting their cut?"
0% found this insightful
Ever wondered what historical figures would say about today's headlines?
Sign up to generate historical perspectives on this story.
26 events
Latest: February 5th, 2026 · 4 months ago
Showing 8 of 26
JK to step
Tap a bar to jump to that date
Jump to
February 2026
FTC Reaches Landmark Settlement with Express Scripts on Insulin Pricing
LatestLegal
Cigna's Express Scripts settles FTC lawsuit alleging anticompetitive rebate practices inflated insulin list prices; no fines but requires 10-year structural reforms including pass-through rebates to patients at point-of-sale starting 2028 and delinking compensation from list prices.
January 2026
FTC Pauses Express Scripts Lawsuit for Settlement Talks
Legal
FTC stays administrative proceedings against Express Scripts and affiliates until July 1, 2026, while negotiating proposed consent agreement—first potential settlement in insulin price lawsuit. Cases against CVS Caremark and OptumRx continue.
Civica Rx Launches $55 Insulin Glargine at Lowest U.S. Market Price
Product Launch
Civica begins distributing insulin glargine-yfgn across U.S. pharmacies at $55 for five pens, significantly undercutting market rates with transparent pricing requiring no insurance forms or copay programs.
California Launches First State-Branded Insulin Program
Product Launch
California becomes first state to sell its own CalRx-branded insulin glargine at $55 per five-pen box through partnership with Civica and Biocon, making California the only state contracting for its own affordable insulin.
California $35 Insulin Copay Cap Takes Effect
Implementation
SB 40 caps insulin copays at $35 for 30-day supply for Californians on private health plans and prohibits step therapy requirements that forced patients to try multiple insulins before coverage approval.
Novo Nordisk's Additional Insulin Price Cuts Take Effect
Price Reduction
Novo Nordisk implements 75% price cut for Fiasp and 72% cut for Tresiba, expanding beyond 2023 reductions.
Trump Administration Secures $35 Insulin Agreements with Manufacturers
Policy
Novo Nordisk commits to providing NovoLog and Tresiba at maximum $35 per month as part of broader pharmaceutical pricing agreements with Trump administration covering insulin and GLP-1 medications.
Sanofi Expands $35 Insulin Access to All Americans
Policy
Sanofi's Insulins Valyou Savings Program now offers 30-day supply of any Sanofi insulin for $35 regardless of insurance status, expanding beyond previous commercial insurance limitation.
October 2025
Civica Announces $55 Insulin Launch Details
Announcement
Civica reveals insulin glargine will sell for $55 per five-pen box starting January 1, 2026.
California Announces CalRx Insulin Launch Details
Announcement
Governor Newsom announces CalRx-branded insulin glargine will launch January 1, 2026 at $11 per pen ($55 per five-pack), making California first state to produce and sell its own insulin.
August 2025
FTC Insulin Lawsuit Resumes After Stay Lifted
Legal
Administrative Law Judge lifts 105-day stay on FTC lawsuit against PBMs as new commissioners appointed; PBMs file motion to dismiss two days later.
December 2024
Novo Nordisk Announces 2026 Price Cuts
Announcement
Novo announces price reductions for Fiasp (75%) and Tresiba (72%) taking effect in 2026, beyond 2023 cuts.
September 2024
FTC Sues Top Pharmacy Benefit Managers
Legal
Federal lawsuit targets CVS Caremark, Express Scripts, OptumRx for creating perverse rebate system inflating insulin prices.
January 2024
Manufacturer Price Cuts Take Effect
Implementation
All three major insulin makers' price reductions go live nationwide.
Novo Nordisk announces NovoLog price cut of 75%, Novolin and Levemir by 65%.
Eli Lilly Cuts Insulin Prices 70%
Price Reduction
Eli Lilly announces 70% price cuts and $35 copay cap following political pressure.
January 2023
Medicare $35 Insulin Cap Takes Effect
Implementation
Medicare beneficiaries pay maximum $35/month for insulin under Inflation Reduction Act.
August 2022
Inflation Reduction Act Passes
Legislation
Law caps Medicare insulin copays at $35/month, taking effect January 2023.
March 2022
Civica Announces Insulin Manufacturing
Announcement
Civica reveals plans to manufacture and distribute affordable insulin glargine, lispro, and aspart.
July 2021
FDA Approves First Interchangeable Insulin Biosimilar
Regulatory
Biocon's insulin glargine-yfgn becomes first interchangeable biosimilar insulin approved in U.S.
April 2020
Minnesota Passes Alec Smith Insulin Affordability Act
Legislation
First-in-nation state law creates emergency insulin program, inspired by Alec Smith's death.
January 2019
Humalog Reaches $332 Per Vial
Price Increase
Humalog price hits $332—a 1,200% increase from $21 in 1999, forcing 1 in 4 diabetics to ration.
January 2018
Civica Rx Founded
Organization
Seven health systems and three philanthropies launch nonprofit pharmaceutical company to combat drug shortages and price gouging.
June 2017
Alec Smith Dies Rationing Insulin
Tragedy
26-year-old Alec Smith found dead from diabetic ketoacidosis after rationing $1,300/month insulin he couldn't afford.
January 1999
Humalog Baseline Price: $21 Per Vial
Reference Point
Eli Lilly's Humalog insulin costs $21 per 10mL vial, establishing baseline before two-decade price escalation.
Historical Context
3 moments from history that rhyme with this story — and how they unfolded.
1 of 3
1984-2000
Generic Drug Price Collapse (1980s-1990s)
The Hatch-Waxman Act of 1984 created abbreviated pathways for generic drug approval, triggering massive price competition. Within years, generic versions of common medications sold for 20-30% of branded prices. Patients who once paid hundreds for antibiotics and blood pressure medications saw costs plummet. The pharmaceutical industry shifted strategy toward newer patented drugs while generic manufacturers proliferated.
Established enduring two-tier pharmaceutical market: cheap generics and expensive branded innovation.
Why this matters now
Civica's biosimilar insulin follows this playbook. If interchangeable biosimilars replicate generic success, insulin pricing could face similar collapse—but biologics are harder to manufacture than small-molecule drugs, creating higher barrier to competition.
2 of 3
2007-2016
EpiPen Price Scandal (2016)
Mylan acquired EpiPen in 2007 and incrementally raised prices from $100 to over $600 for a two-pack by 2016—a 500% increase for a life-saving allergy treatment with minimal manufacturing cost. Parents, schools, and patient advocates erupted in protest. Congressional hearings grilled Mylan's CEO. The backlash triggered generic competition, Mylan's own generic version, and permanent reputational damage.
Then
Mylan launched generic EpiPen at $300; competitors entered market.
Now
Prices stabilized but never returned to pre-gouging levels. Mylan merged with Upjohn in 2020.
Why this matters now
The insulin crisis mirrors EpiPen dynamics: monopolistic market, life-or-death product, incremental price increases that suddenly became politically intolerable. Both required patient deaths and public outrage to trigger manufacturer response—showing voluntary price cuts come only under existential threat.
3 of 3
1987-2003
AIDS Drug Pricing Crisis and Generic Manufacturing (1990s-2000s)
When antiretroviral drugs emerged in the mid-1990s, pharmaceutical companies charged $10,000-15,000 annually per patient—pricing that condemned millions in developing countries to death. Activist pressure and generic manufacturers in India and Brazil began producing identical drugs for $300-500 annually. The price differential became morally and politically unsustainable. By 2003, major manufacturers slashed prices for developing markets, and organizations like PEPFAR negotiated bulk purchase agreements using generic competition as leverage.
Then
Generic competition forced 90% price reductions in developing countries by 2005.
Now
Established tiered pricing models and normalized generic antiretrovirals, saving millions of lives.
Why this matters now
Demonstrates that nonprofit and low-cost manufacturers can break pharmaceutical pricing strangleholds when producing essential medicines. Civica plays similar role domestically that Indian generic manufacturers played globally—using manufacturing capacity to challenge unjustifiable pricing on life-saving drugs. The lesson: competition works, but requires actual alternative suppliers, not just political pressure.
